Cross-source evidence timeline
Vasopressin research timeline
Follow 83 selected, directly cited source records from September 25, 1998 through November 5, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Literature metadata
Oxytocin, vasopressin, and their crosstalk in sexually-dimorphic psychiatric conditions.↗
PubMed lists PMID 41862144 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 18, 2026 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance).↗
PubMed lists PMID 39438674 in Nature reviews. Nephrology as Journal Article, Review, Consensus Statement, with publication-date metadata of 2024-10-22 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 22, 2024 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT05958342↗
PeptideScanner retained ClinicalTrials.gov record NCT05958342 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT04501861↗
PeptideScanner retained ClinicalTrials.gov record NCT04501861 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT07633600↗
PeptideScanner retained ClinicalTrials.gov record NCT07633600 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Literature metadata
Management of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in Neonates and Infants.↗
PubMed lists PMID 40602377 in Hormone research in paediatrics as Journal Article, Review, with publication-date metadata of 2025-07-02 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 2, 2025 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
A Scoping Review on Salivary Oxytocin and Vasopressin Measurement in the Dog.↗
PubMed lists PMID 40867749 in Animals : an open access journal from MDPI as Journal Article, Review, with publication-date metadata of 2025-08-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 18, 2025 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Arginine vasopressin deficiency: towards a better characterization.↗
PubMed lists PMID 42677919 in Endocrine-related cancer as Journal Article, Review, with publication-date metadata of 2026-09-01 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 1, 2026 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
The vasopressin system as an immunoneuroendocrine therapeutic target in inflammatory conditions.↗
PubMed lists PMID 42647984 in Current opinion in pharmacology as Journal Article, Review, with publication-date metadata of 2026-08-10 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 10, 2026 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT06709573↗
PeptideScanner retained ClinicalTrials.gov record NCT06709573 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Literature metadata
From cranial diabetes insipidus to vasopressin deficiency: terminology, tests and treatment.↗
PubMed lists PMID 41667271 in Archives of disease in childhood as Journal Article, Review, Case Reports, with publication-date metadata of 2026-08-19 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 19, 2026 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Important Role of Renin-Angiotensin System and Vasopressin System in Cardiovascular, Metabolic and Psychogenic Disorders in Pregnancy and Early Postnatal Life: A Narrative Review.↗
PubMed lists PMID 42653310 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-08-16 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 16, 2026 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Pharmacological mechanisms and clinical evidence of vasopressin, steroids, and epinephrine triple therapy in in-hospital cardiac arrest.↗
PubMed lists PMID 42609684 in Frontiers in cardiovascular medicine as Journal Article, Review, with publication-date metadata of 2026-08-03 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 3, 2026 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic.↗
PubMed lists PMID 41363127 in The Journal of clinical endocrinology and metabolism as Journal Article, Review, with publication-date metadata of 2026-03-17 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 17, 2026 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Vasopressin 1a Receptor Antagonists for Pathological Aggression in Neurodegenerative and Other CNS Diseases.↗
PubMed lists PMID 42072430 in Biomedicines as Journal Article, Review, with publication-date metadata of 2026-04-14 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 14, 2026 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Vasopressin Versus Norepinephrine As First-Line Vasopressor Therapy for Vasoplegic Shock Following Cardiac Surgery: A Systematic Review.↗
PubMed lists PMID 42583609 in Cureus as Journal Article, Review, with publication-date metadata of 2026-07-12 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 12, 2026 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT06217562↗
PeptideScanner retained ClinicalTrials.gov record NCT06217562 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Literature metadata
Acquired transient vasopressin deficiency by cannabinoids and other substances.↗
PubMed lists PMID 41668460 in Endocrinology as Journal Article, Review, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 6, 2026 · day precisionAdded to PeptideScanner November 15, 2026Regulatory
Federal Register notice 2026-13492↗
The Federal Register published notice 2026-13492, attributed to FDA and its parent HHS department, on 2026-07-06. Its official title is “Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗
Added to PeptideScanner November 15, 2026Literature metadata
Pediatric Central Diabetes Insipidus due to Arginine Vasopressin Deficiency in the Perianesthetic Period.↗
PubMed lists PMID 41552892 in Paediatric anaesthesia as Journal Article, Review, with publication-date metadata of 2026-01-19 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 19, 2026 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Role of oxytocin and vasopressin in alcohol use disorder.↗
PubMed lists PMID 39523056 in International review of neurobiology as Journal Article, Review, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural, with publication-date metadata of 2024-10-08 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 8, 2024 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT04592744↗
PeptideScanner retained ClinicalTrials.gov record NCT04592744 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Regulatory
Federal Register notice 2026-11062↗
The Federal Register published notice 2026-11062, attributed to FDA and its parent HHS department, on 2026-06-03. Its official title is “Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT07614438↗
PeptideScanner retained ClinicalTrials.gov record NCT07614438 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-06-02, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA212068↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 212068 with status AP dated 2026-05-06, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA212069↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 212069 with status AP dated 2026-05-06, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Literature metadata
Vasopressin and steroids in addition to adrenaline in cardiac arrest (VAST-A) - A randomised pilot study.↗
PubMed lists PMID 40154876 in Resuscitation as Journal Article, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-03-26 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 26, 2025 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT05738148↗
PeptideScanner retained ClinicalTrials.gov record NCT05738148 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Literature metadata
Plasma concentrations of peptide hormones: Unrealistic levels of vasopressin (AVP), oxytocin (OXT), and brain natriuretic peptide (BNP).↗
PubMed lists PMID 39034759 in Acta physiologica (Oxford, England) as Journal Article, Review, with publication-date metadata of 2024-07-22 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 22, 2024 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT02118467↗
PeptideScanner retained ClinicalTrials.gov record NCT02118467 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Literature metadata
Arginine Vasopressin (AVP) Deficiency: Diagnosis and Treatment - An Update.↗
PubMed lists PMID 41497289 in Indian journal of endocrinology and metabolism as Journal Article, Review, with publication-date metadata of 2025-12-19 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 19, 2025 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Copeptin as a Marker for Vasopressin Dysregulation and Diagnosis.↗
PubMed lists PMID 41070791 in The journal of applied laboratory medicine as Journal Article, Review, with publication-date metadata of 2026-01-05 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 5, 2026 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2025
Literature metadata
Arginine vasopressin deficiency after surgical ligation of an unruptured anterior communicating artery aneurysm - a case report and literature review.↗
PubMed lists PMID 41341140 in Frontiers in endocrinology as Journal Article, Case Reports, Review, with publication-date metadata of 2025-11-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 18, 2025 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT05568160↗
PeptideScanner retained ClinicalTrials.gov record NCT05568160 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Literature metadata
Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?↗
PubMed lists PMID 40731360 in Critical care (London, England) as Journal Article, Review, with publication-date metadata of 2025-07-29 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 29, 2025 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Vasopressin in traumatic hemorrhagic shock.↗
PubMed lists PMID 39936940 in Current opinion in anaesthesiology as Journal Article, Systematic Review, with publication-date metadata of 2025-01-20 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 20, 2025 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Evidence for the contribution of vasopressin V1B receptors in the pathophysiology of depression.↗
PubMed lists PMID 39608503 in Biochemical pharmacology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-11-26 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 26, 2024 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Aptamers and MIPs as alternative molecular recognition elements for vasopressin and oxytocin sensing: A review.↗
PubMed lists PMID 40023907 in Biosensors & bioelectronics as Journal Article, Review, with publication-date metadata of 2025-02-23 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 23, 2025 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT06547892↗
PeptideScanner retained ClinicalTrials.gov record NCT06547892 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-04-13, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Literature metadata
Arginine vasopressin and copeptin: comparative review and perspective in veterinary medicine.↗
PubMed lists PMID 40160705 in Frontiers in veterinary science as Journal Article, Review, with publication-date metadata of 2025-03-14 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 14, 2025 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT05506319↗
PeptideScanner retained ClinicalTrials.gov record NCT05506319 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Literature metadata
Hyponatremia due to preserved non-osmotic arginine vasopressin secretion in adipsic diabetes insipidus: a case report with review of literature.↗
PubMed lists PMID 39111874 in Endocrine journal as Case Reports, Journal Article, Review, with publication-date metadata of 2024-08-07 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 7, 2024 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Hemodynamic Management with Vasopressin for Cardiovascular Surgery.↗
PubMed lists PMID 39768943 in Medicina (Kaunas, Lithuania) as Journal Article, Review, with publication-date metadata of 2024-12-16 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 16, 2024 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
[Revisiting the vasopressin V2 receptor].↗
PubMed lists PMID 39780566 in Sheng li xue bao : [Acta physiologica Sinica] as Journal Article, Review, English Abstract, with publication-date metadata of 2024-12-25 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 25, 2024 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2024
Literature metadata
The Role of Oxytocin and Vasopressin in People with Borderline Personality Disorder: A Closer Look at Adolescents.↗
PubMed lists PMID 39596113 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2024-11-09 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 9, 2024 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT02975999↗
PeptideScanner retained ClinicalTrials.gov record NCT02975999 at 2026-11-15T22:08:31.832Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Literature metadata
Arginine vasopressin deficiency onset after COVID-19 vaccination with positive anti-rabphilin-3A antibodies: a case report and literature review.↗
PubMed lists PMID 39107738 in BMC endocrine disorders as Case Reports, Journal Article, Review, with publication-date metadata of 2024-08-06 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 6, 2024 · day precisionAdded to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application NDA217766↗
The official Drugs@FDA dataset lists original submission 1 for NDA 217766 with status AP dated 2024-07-11, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA213988↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 213988 with status AP dated 2024-05-08, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA216963↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 216963 with status AP dated 2024-02-09, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026
Source year
2023
Regulatory
Drugs@FDA application ANDA217987↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 217987 with status AP dated 2023-12-06, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application NDA217569↗
The official Drugs@FDA dataset lists original submission 1 for NDA 217569 with status AP dated 2023-09-29, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA213206↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 213206 with status AP dated 2023-05-26, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026
Source year
2022
Regulatory
Drugs@FDA application ANDA214314↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 214314 with status AP dated 2022-08-15, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA212944↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 212944 with status AP dated 2022-08-05, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA211857↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 211857 with status AP dated 2022-07-18, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026
Source year
2021
Regulatory
Drugs@FDA application ANDA211538↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 211538 with status AP dated 2021-12-15, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026
Source year
2020
Regulatory
Federal Register notice 2020-26133↗
The Federal Register published notice 2020-26133, attributed to FDA and its parent HHS department, on 2020-11-25. Its official title is “Termination of the Food and Drug Administration's Unapproved Drugs Initiative; Request for Information Regarding Drugs Potentially Generally Recognized as Safe and Effective,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application NDA212593↗
The official Drugs@FDA dataset lists original submission 1 for NDA 212593 with status AP dated 2020-08-03, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Federal Register notice 2020-16649↗
The Federal Register published notice 2020-16649, attributed to FDA and its parent HHS department, on 2020-07-31. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗
Added to PeptideScanner November 15, 2026
Source year
2019
Clinical trials
ClinicalTrials.gov record NCT01093768↗
PeptideScanner retained ClinicalTrials.gov record NCT01093768 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-12-17, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00628550↗
PeptideScanner retained ClinicalTrials.gov record NCT00628550 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-09-17, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Regulatory
Federal Register notice 2019-18932↗
The Federal Register published notice 2019-18932, attributed to FDA and its parent HHS department, on 2019-09-03. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01962870↗
PeptideScanner retained ClinicalTrials.gov record NCT01962870 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-05-24, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01611935↗
PeptideScanner retained ClinicalTrials.gov record NCT01611935 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-05-21, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT03930069↗
PeptideScanner retained ClinicalTrials.gov record NCT03930069 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-04-29, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01800877↗
PeptideScanner retained ClinicalTrials.gov record NCT01800877 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-03-12, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Regulatory
Federal Register notice 2019-03810↗
The Federal Register published notice 2019-03810, attributed to FDA and its parent HHS department, on 2019-03-04. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01318278↗
PeptideScanner retained ClinicalTrials.gov record NCT01318278 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-02-20, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026
Source year
2018
Clinical trials
ClinicalTrials.gov record NCT00886262↗
PeptideScanner retained ClinicalTrials.gov record NCT00886262 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-10-17, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Regulatory
Federal Register notice 2018-18614↗
The Federal Register published notice 2018-18614, attributed to FDA and its parent HHS department, on 2018-08-28. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01718613↗
PeptideScanner retained ClinicalTrials.gov record NCT01718613 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-05-18, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01393704↗
PeptideScanner retained ClinicalTrials.gov record NCT01393704 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026
Source year
2017
Clinical trials
ClinicalTrials.gov record NCT02223429↗
PeptideScanner retained ClinicalTrials.gov record NCT02223429 at 2026-11-15T22:08:31.832Z. Its registry update date was 2017-06-05, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00358579↗
PeptideScanner retained ClinicalTrials.gov record NCT00358579 at 2026-11-15T22:08:31.832Z. Its registry update date was 2017-03-17, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026
Source year
2016
Clinical trials
ClinicalTrials.gov record NCT01861015↗
PeptideScanner retained ClinicalTrials.gov record NCT01861015 at 2026-11-15T22:08:31.832Z. Its registry update date was 2016-01-22, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026
Source year
2015
Clinical trials
ClinicalTrials.gov record NCT00748072↗
PeptideScanner retained ClinicalTrials.gov record NCT00748072 at 2026-11-15T22:08:31.832Z. Its registry update date was 2015-01-13, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026
Source year
2014
Clinical trials
ClinicalTrials.gov record NCT00379522↗
PeptideScanner retained ClinicalTrials.gov record NCT00379522 at 2026-11-15T22:08:31.832Z. Its registry update date was 2014-11-05, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application NDA204485↗
The official Drugs@FDA dataset lists original submission 1 for NDA 204485 with status AP dated 2014-04-17, and names vasopressin among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026
Source year
2013
Clinical trials
ClinicalTrials.gov record NCT01700478↗
PeptideScanner retained ClinicalTrials.gov record NCT01700478 at 2026-11-15T22:08:31.832Z. Its registry update date was 2013-02-11, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026
Source year
2012
Regulatory
Federal Register notice 2012-12040↗
The Federal Register published notice 2012-12040, attributed to FDA and its parent HHS department, on 2012-05-18. Its official title is “Determination That PITRESSIN TANNATE IN OIL (Vasopressin Tannate) Injection, 5 Pressor Units/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗
Added to PeptideScanner November 15, 2026
Source year
2006
Clinical trials
ClinicalTrials.gov record NCT00269685↗
PeptideScanner retained ClinicalTrials.gov record NCT00269685 at 2026-11-15T22:08:31.832Z. Its registry update date was 2006-05-29, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Added to PeptideScanner November 15, 2026
Source year
1998
Regulatory
Federal Register notice 98-25713↗
The Federal Register published notice 98-25713, attributed to FDA and its parent HHS department, on 1998-09-25. Its official title is “Parke-Davis Pharmaceutical Research et al.; Withdrawal of Approval of 14 New Drug Applications and 13 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗
Added to PeptideScanner November 15, 2026